טוען...
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affec...
שמור ב:
| הוצא לאור ב: | Korean J Intern Med |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Association of Internal Medicine
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6718771/ https://ncbi.nlm.nih.gov/pubmed/29950554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2018.011 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|